Traders should monitor the DDW presentations (May 3–5) and investor event (May 4) for early clinical signals from the RESOLVE trial, which could influence sentiment around EP-104GI's development path. Absent new data here, material movement is unlikely until actual results are released.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals announced it will present four abstracts at the Digestive Disease Week (DDW) 2026 meeting, including clinical data from the ongoing Phase 1b/2 RESOLVE trial of its lead candidate EP-104GI for eosinophilic esophagitis (EoE). The company will also host a virtual investor event featuring key opinion leaders and management to discuss the drug's potential in preventing esophageal strictures.
Key Facts
- Eupraxia will present 4 abstracts at DDW 2026 (May 2–5, Chicago), including one oral and three poster presentations on EP-104GI.
- Data from the Phase 1b/2 RESOLVE trial will be shared, focusing on histological, endoscopic, and dysphagia outcomes over 36 weeks.
- An investor event is scheduled for May 4, 2026, featuring KOLs and company management to highlight EP-104GI's potential.
- EP-104GI is a long-acting submucosal corticosteroid formulation for EoE, delivered via injection into the esophageal wall.
- No new clinical results are disclosed in this filing—only upcoming presentations are announced.
Financial Impact
No direct financial impact disclosed; this is a forward-looking event announcement.
Risk Factors
- Clinical data from RESOLVE may not meet expectations, especially given the small sample size typical of Phase 1b/2 trials.
- Investor event could highlight competitive or regulatory challenges not currently priced in.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002633 |
| Document: f6k_042126.htm | 0001171843-26-002633 |
| Document: 0001171843-26-002633-index-headers.html | 0001171843-26-002633 |
| Document: 0001171843-26-002633-index.html | 0001171843-26-002633 |
| Document: 0001171843-26-002633.txt | 0001171843-26-002633 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $7.59 | awaiting T+5 | — | $7.08 (−6.72%) |
Oct 15, 2026 12d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $7.08 (+4.58%) |
Oct 9, 2026 18d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $7.08 (−5.09%) |
Sep 30, 2026 27d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $7.08 (−22.20%) |
Sep 30, 2026 27d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $7.08 (−22.20%) |
Aug 25, 2026 9w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $7.08 (+4.58%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $7.08 (+6.15%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $7.08 (+9.26%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $7.08 (+8.59%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $7.08 (+6.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers